| Mark L Benson, MD | |
|
1 Medical Park, Wheeling, WV 26003-6379 | |
| (304) 243-3270 | |
| Not Available |
| Full Name | Mark L Benson |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 35 Years |
| Location | 1 Medical Park, Wheeling, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023085875 | NPI | - | NPPES |
| 0120734000 | Medicaid | WV | |
| 0015422180001 | Medicaid | PA | |
| 0181299 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 16770 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Princeton Community Hospital | Princeton, WV | Hospital |
| Wheeling Hospital | Wheeling, WV | Hospital |
| Reynolds Memorial Hospital | Glen dale, WV | Hospital |
| Weirton Medical Center | Weirton, WV | Hospital |
| Wetzel County Hospital | New martinsville, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology Associates Inc | 0446210520 | 18 |
| Radiology Associates Inc | 0446210520 | 18 |
News Archive
A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal first quarter ended July 31, 2011.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
› Verified 6 days ago
| Entity Name | Radiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982671889 PECOS PAC ID: 0446210520 Enrollment ID: O20041013000672 |
News Archive
A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal first quarter ended July 31, 2011.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark L Benson, MD Po Box 5307, Lima, OH 45802-5307 Ph: (866) 497-8222 | Mark L Benson, MD 1 Medical Park, Wheeling, WV 26003-6379 Ph: (304) 243-3270 |
News Archive
A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal first quarter ended July 31, 2011.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
› Verified 6 days ago
Terry L Stake, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3270 | |
Brian Schambach, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3000 | |
Vincent J Caruso, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3270 | |
Gurijala N Reddy, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 6 Fieldcrest Ave, Wheeling, WV 26003 Phone: 304-281-7928 | |
John L Defilippo, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3270 | |
Vicente P Almario, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-0123 |